Cytochrome P450 ω-Hydroxylases in Inflammation and Cancer

Advances in Pharmacology

Volumn 74, Issue , 2015, Pages 223-262

  Johnson, Amanda L ^a   Edson, Katheryne Z ^a,b   Totah, Rheem A ^a   Rettie, Allan E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b AMGEN INC   (United States)

Author keywords

20 HETE; Arachidonic acid; Cancer; CYP4; Cytochrome P450; Eicosanoids; Fatty acids; Inflammation; Leukotrienes; Omega hydroxylases

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; 20 HYDROXYLEUKOTRIENE B4; ARACHIDONIC ACID; BIOLOGICAL MARKER; CYTOCHROME P450; ICOSANOID; LEUKOTRIENE B4; OXYGENASE; POLYUNSATURATED FATTY ACID; CYTOCHROME P-450 OMEGA-HYDROXYLASE; CYTOCHROME P450 4A;

ANGIOGENESIS; CANCER GROWTH; CATABOLISM; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME SUBSTRATE; GENE CONTROL; HUMAN; INFLAMMATION; LIPID ANALYSIS; NEOPLASM; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; HYDROXYLATION; METABOLISM; PHYSIOLOGY;

ARACHIDONIC ACID; CYTOCHROME P-450 CYP4A; CYTOCHROME P-450 ENZYME SYSTEM; EICOSANOIDS; HUMANS; HYDROXYLATION; INFLAMMATION; NEOPLASMS;

EID: 84932147915     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/bs.apha.2015.05.002     Document Type: Chapter

References (167)

1. Aebersold R., Burlingame A.L., Bradshaw R.A. Western blots versus selected reaction monitoring assays: Time to turn the tables?. Molecular & Cellular Proteomics 2013, 12:2381-2382.
2. Alexanian A., Miller B., Roman R.J., Sorokin A. 20-HETE-producing enzymes are up-regulated in human cancers. Cancer Genomics Proteomics 2012, 9:163-169.
3. Alexanian A., Rufanova V.A., Miller B., Flasch A., Roman R.J., Sorokin A. Down-regulation of 20-HETE synthesis and signaling inhibits renal adenocarcinoma cell proliferation and tumor growth. Anticancer Research 2009, 29:3819-3824.
4. Alexanian A., Sorokin A. Targeting 20-HETE producing enzymes in cancer-Rationale, pharmacology, and clinical potential. Onco Targets and therapy 2013, 6:243-255.
5. Amaral S.L., Maier K.G., Schippers D.N., Roman R.J., Greene A.S. CYP4A metabolites of arachidonic acid and VEGF are mediators of skeletal muscle angiogenesis. American Journal of Physiology. Heart and Circulatory Physiology 2003, 284:H1528-H1535.
6. Aoyama T., Hardwick J.P., Imaoka S., Funae Y., Gelboin H.V., Gonzalez F.J. Clofibrate-inducible rat hepatic P450s IVA1 and IVA3 catalyze the omega- and (omega-1)-hydroxylation of fatty acids and the omega-hydroxylation of prostaglandins E1 and F2 alpha. Journal of Lipid Research 1990, 31:1477-1482.
7. Arita M., Oh S.F., Chonan T., Hong S., Elangovan S., Sun Y.P., et al. Metabolic inactivation of resolvin E1 and stabilization of its anti-inflammatory actions. The Journal of Biological Chemistry 2006, 281:22847-22854.
8. Arnold C., Markovic M., Blossey K., Wallukat G., Fischer R., Dechend R., et al. Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of (omega)-3 fatty acids. The Journal of Biological Chemistry 2010, 285:32720-32733.
9. Bardowell S.A., Duan F., Manor D., Swanson J.E., Parker R.S. Disruption of mouse cytochrome p450 4f14 (Cyp4f14 gene) causes severe perturbations in vitamin E metabolism. The Journal of Biological Chemistry 2012, 287:26077-26086.
10. Bednar M.M., Schwartzman M., Ibraham N.G., McGiff J.C., Mullane K.M. Conversion of arachidonic acid to two novel products by a cytochrome P450-dependent mixed-function oxidase in polymorphonuclear leukocytes. Biochemical and Biophysical Research Communications 1984, 123:581-588.
11. Berry K.A., Borgeat P., Gosselin J., Flamand L., Murphy R.C. Urinary metabolites of leukotriene B4 in the human subject. The Journal of Biological Chemistry 2003, 278:24449-24460.
12. Birnie M., Morrison R., Camara R., Strauss K.I. Temporal changes of cytochrome P450 (Cyp) and eicosanoid-related gene expression in the rat brain after traumatic brain injury. BMC Genomics 2013, 14:303.
13. Bylund J., Hidestrand M., Ingelman-Sundberg M., Oliw E.H. Identification of CYP4F8 in human seminal vesicles as a prominent 19-hydroxylase of prostaglandin endoperoxides. The Journal of Biological Chemistry 2000, 275:21844-21849.
14. Capdevila J., Chacos N., Werringloer J., Prough R.A., Estabrook R.W. Liver microsomal cytochrome P-450 and the oxidative metabolism of arachidonic acid. Proceedings of the National Academy of Sciences of the United States of America 1981, 78:5362-5366.
15. Capdevila J.H., Falck J.R. Biochemical and molecular properties of the cytochrome P450 arachidonic acid monooxygenases. Prostaglandins & Other Lipid Mediators 2002, 68-69:325-344.
16. Chen L., Ackerman R., Saleh M., Gotlinger K.H., Kessler M., Mendelowitz L.G., et al. 20-HETE regulates the angiogenic functions of human endothelial progenitor cells and contributes to angiogenesis in vivo. The Journal of Pharmacology and Experimental Therapeutics 2014, 348:442-451.
17. Chen L., Hardwick J.P. Identification of a new P450 subfamily, CYP4F1, expressed in rat hepatic tumors. Archives of Biochemistry and Biophysics 1993, 300:18-23.
18. Cheng J., Edin M.L., Hoopes S.L., Li H., Bradbury J.A., Graves J.P., et al. Vascular characterization of mice with endothelial expression of cytochrome P450 4F2. The FASEB Journal 2014, 28:2915-2931.
19. Christmas P., Jones J.P., Patten C.J., Rock D.A., Zheng Y., Cheng S.M., et al. Alternative splicing determines the function of CYP4F3 by switching substrate specificity. The Journal of Biological Chemistry 2001, 276:38166-38172.
20. Christmas P., Ursino S.R., Fox J.W., Soberman R.J. Expression of the CYP4F3 gene. Tissue-specific splicing and alternative promoters generate high and low K(m) forms of leukotriene B(4) omega-hydroxylase. The Journal of Biological Chemistry 1999, 274:21191-21199.
21. Cowart L.A., Wei S., Hsu M.H., Johnson E.F., Krishna M.U., Falck J.R., et al. The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands. The Journal of Biological Chemistry 2002, 277:35105-35112.
22. D'Angelo G., Struman I., Martial J., Weiner R.I. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:6374-6378.
23. Dawczynski C., Massey K.A., Ness C., Kiehntopf M., Stepanow S., Platzer M., et al. Randomized placebo-controlled intervention with n-3 LC-PUFA-supplemented yoghurt: Effects on circulating eicosanoids and cardiovascular risk factors. Clinical Nutrition 2013, 32:686-696.
24. Dhar M., Sepkovic D.W., Hirani V., Magnusson R.P., Lasker J.M. Omega oxidation of 3-hydroxy fatty acids by the human CYP4F gene subfamily enzyme CYP4F11. Journal of Lipid Research 2008, 49:612-624.
25. Downie D., McFadyen M.C., Rooney P.H., Cruickshank M.E., Parkin D.E., Miller I.D., et al. Profiling cytochrome P450 expression in ovarian cancer: Identification of prognostic markers. Clinical Cancer Research 2005, 11:7369-7375.
26. Draye J.P., Vamecq J. The gluconeogenicity of fatty acids in mammals. Trends in Biochemical Sciences 1989, 14:478-479.
27. Du L., Yin H., Morrow J.D., Strobel H.W., Keeney D.S. 20-Hydroxylation is the CYP-dependent and retinoid-inducible leukotriene B4 inactivation pathway in human and mouse skin cells. Archives of Biochemistry and Biophysics 2009, 484:80-86.
28. Edson K.Z., Prasad B., Unadkat J.D., Suhara Y., Okano T., Guengerich F.P., et al. Cytochrome P450-dependent catabolism of vitamin K: Omega-hydroxylation catalyzed by human CYP4F2 and CYP4F11. Biochemistry 2013, 52:8276-8285.
29. Eksterowicz J., Rock D.A., Rock B.M., Wienkers L.C., Foti R.S. Characterization of the active site properties of CYP4F12. Drug Metabolism and Disposition 2014, 42:1698-1707.
30. Fan F., Muroya Y., Roman R.J. Cytochrome P450 eicosanoids in hypertension and renal disease. Current Opinion in Nephrology and Hypertension 2015, 24:37-46.
31. Fer M., Corcos L., Dreano Y., Plee-Gautier E., Salaun J.P., Berthou F., et al. Cytochromes P450 from family 4 are the main omega hydroxylating enzymes in humans: CYP4F3B is the prominent player in PUFA metabolism. Journal of Lipid Research 2008, 49:2379-2389.
32. Fleming I. Vascular cytochrome p450 enzymes: Physiology and pathophysiology. Trends in Cardiovascular Medicine 2008, 18:20-25.
33. Folkman J. Tumor angiogenesis: Therapeutic implications. The New England Journal of Medicine 1971, 285:1182-1186.
34. Forrester L.M., Hayes J.D., Millis R., Barnes D., Harris A.L., Schlager J.J., et al. Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue. Carcinogenesis 1990, 11:2163-2170.
35. Funk C.D. Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 2001, 294:1871-1875.
36. Gandhi A.V., Saxena S., Relles D., Sarosiek K., Kang C.Y., Chipitsyna G., et al. Differential expression of cytochrome P450 omega-hydroxylase isoforms and their association with clinicopathological features in pancreatic ductal adenocarcinoma. Annals of Surgical Oncology 2013, 20(Suppl. 3):S636-S643.
37. Gatica A., Aguilera M.C., Contador D., Loyola G., Pinto C.O., Amigo L., et al. P450 CYP2C epoxygenase and CYP4A omega-hydroxylase mediate ciprofibrate-induced PPARalpha-dependent peroxisomal proliferation. Journal of Lipid Research 2007, 48:924-934.
38. Gibson G.G., Orton T.C., Tamburini P.P. Cytochrome P-450 induction by clofibrate. Purification and properties of a hepatic cytochrome P-450 relatively specific for the 12- and 11-hydroxylation of dodecanoic acid (lauric acid). The Biochemical Journal 1982, 203:161-168.
39. Gonzalez F.J., Shah Y.M. PPARalpha: Mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 2008, 246:2-8.
40. Gronert K., Clish C.B., Romano M., Serhan C.N. Transcellular regulation of eicosanoid biosynthesis. Methods in Molecular Biology 1999, 120:119-144.
41. Guo A.M., Arbab A.S., Falck J.R., Chen P., Edwards P.A., Roman R.J., et al. Activation of vascular endothelial growth factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced endothelial cell proliferation. The Journal of Pharmacology and Experimental Therapeutics 2007, 321:18-27.
42. Guo A.M., Janic B., Sheng J., Falck J.R., Roman R.J., Edwards P.A., et al. The cytochrome P450 4A/F-20-hydroxyeicosatetraenoic acid system: A regulator of endothelial precursor cells derived from human umbilical cord blood. The Journal of Pharmacology and Experimental Therapeutics 2011, 338:421-429.
43. Guo M., Roman R.J., Falck J.R., Edwards P.A., Scicli A.G. Human U251 glioma cell proliferation is suppressed by HET0016 [N-hydroxy-N'-(4-butyl-2-methylphenyl)formamidine], a selective inhibitor of CYP4A. The Journal of Pharmacology and Experimental Therapeutics 2005, 315:526-533.
44. Guo M., Roman R.J., Fenstermacher J.D., Brown S.L., Falck J.R., Arbab A.S., et al. 9L gliosarcoma cell proliferation and tumor growth in rats are suppressed by N-hydroxy-N'-(4-butyl-2-methylphenol) formamidine (HET0016), a selective inhibitor of CYP4A. The Journal of Pharmacology and Experimental Therapeutics 2006, 317:97-108.
45. Guo A.M., Sheng J., Scicli G.M., Arbab A.S., Lehman N.L., Edwards P.A., et al. Expression of CYP4A1 in U251 human glioma cell induces hyperproliferative phenotype in vitro and rapidly growing tumors in vivo. The Journal of Pharmacology and Experimental Therapeutics 2008, 327:10-19.
46. Guo Y., Zhang W., Giroux C., Cai Y., Ekambaram P., Dilly A.K., et al. Identification of the orphan G protein-coupled receptor GPR31 as a receptor for 12-(S)-hydroxyeicosatetraenoic acid. The Journal of Biological Chemistry 2011, 286:33832-33840.
47. Haeggstrom J.Z., Funk C.D. Lipoxygenase and leukotriene pathways: Biochemistry, biology, and roles in disease. Chemical Reviews 2011, 111:5866-5898.
48. Hammond V.J., O'Donnell V.B. Esterified eicosanoids: Generation, characterization and function. Biochimica et Biophysica Acta 2012, 1818:2403-2412.
49. Hansson G., Lindgren J.A., Dahlen S.E., Hedqvist P., Samuelsson B. Identification and biological activity of novel omega-oxidized metabolites of leukotriene B4 from human leukocytes. FEBS Letters 1981, 130:107-112.
50. Hardwick J.P. Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochemical Pharmacology 2008, 75:2263-2275.
51. Harmon S.D., Fang X., Kaduce T.L., Hu S., Raj Gopal V., Falck J.R., et al. Oxygenation of omega-3 fatty acids by human cytochrome P450 4F3B: Effect on 20-hydroxyeicosatetraenoic acid production. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2006, 75:169-177.
52. Harvey R.D., Morgan E.T. Cancer, inflammation, and therapy: Effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents. Clinical Pharmacology and Therapeutics 2014, 96:449-457.
53. Hashizume T., Imaoka S., Mise M., Terauchi Y., Fujii T., Miyazaki H., et al. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. The Journal of Pharmacology and Experimental Therapeutics 2002, 300:298-304.
54. He X., Cryle M.J., De Voss J.J., de Montellano P.R. Calibration of the channel that determines the omega-hydroxylation regiospecificity of cytochrome P4504A1: Catalytic oxidation of 12-HALODOdecanoic acids. The Journal of Biological Chemistry 2005, 280:22697-22705.
55. Hertz R., Sheena V., Kalderon B., Berman I., Bar-Tana J. Suppression of hepatocyte nuclear factor-4alpha by acyl-CoA thioesters of hypolipidemic peroxisome proliferators. Biochemical Pharmacology 2001, 61:1057-1062.
56. Holla V.R., Adas F., Imig J.D., Zhao X., Price E., Olsen N., et al. Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:5211-5216.
57. Hoopes S.L., Garcia V., Edin M.L., Schwartzman M.L., Zeldin D.C. Vascular actions of 20-HETE. Prostaglandins & Other Lipid Mediators 2015, (Epub ahead of print).
58. Hsu M.H., Savas U., Griffin K.J., Johnson E.F. Human cytochrome p450 family 4 enzymes: Function, genetic variation and regulation. Drug Metabolism Reviews 2007, 39:515-538.
59. Hsu M.H., Savas U., Griffin K.J., Johnson E.F. Regulation of human cytochrome P450 4F2 expression by sterol regulatory element-binding protein and lovastatin. The Journal of Biological Chemistry 2007, 282:5225-5236.
60. Hsu M.H., Savas U., Lasker J.M., Johnson E.F. Genistein, resveratrol, and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside induce cytochrome P450 4F2 expression through an AMP-activated protein kinase-dependent pathway. The Journal of Pharmacology and Experimental Therapeutics 2011, 337:125-136.
61. Ishizuka T., Cheng J., Singh H., Vitto M.D., Manthati V.L., Falck J.R., et al. 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-kappaB activation and the production of inflammatory cytokines in human endothelial cells. The Journal of Pharmacology and Experimental Therapeutics 2008, 324:103-110.
62. Jiang M., Mezentsev A., Kemp R., Byun K., Falck J.R., Miano J.M., et al. Smooth muscle-specific expression of CYP4A1 induces endothelial sprouting in renal arterial microvessels. Circulation Research 2004, 94:167-174.
63. Jiang J.G., Ning Y.G., Chen C., Ma D., Liu Z.J., Yang S., et al. Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Research 2007, 67:6665-6674.
64. Jin R., Koop D.R., Raucy J.L., Lasker J.M. Role of human CYP4F2 in hepatic catabolism of the proinflammatory agent leukotriene B4. Archives of Biochemistry and Biophysics 1998, 359:89-98.
65. Johnson E.F., Palmer C.N., Griffin K.J., Hsu M.H. Role of the peroxisome proliferator-activated receptor in cytochrome P450 4A gene regulation. The FASEB Journal 1996, 10:1241-1248.
66. Kalsotra A., Anakk S., Brommer C.L., Kikuta Y., Morgan E.T., Strobel H.W. Catalytic characterization and cytokine mediated regulation of cytochrome P450 4Fs in rat hepatocytes. Archives of Biochemistry and Biophysics 2007, 461:104-112.
67. Kalsotra A., Du L., Wang Y., Ladd P.A., Kikuta Y., Duvic M., et al. Inflammation resolved by retinoid X receptor-mediated inactivation of leukotriene signaling pathways. The FASEB Journal 2008, 22:538-547.
68. Kalsotra A., Strobel H.W. Cytochrome P450 4F subfamily: At the crossroads of eicosanoid and drug metabolism. Pharmacology & Therapeutics 2006, 112:589-611.
69. Kalsotra A., Turman C.M., Kikuta Y., Strobel H.W. Expression and characterization of human cytochrome P450 4F11: Putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicology and Applied Pharmacology 2004, 199:295-304.
70. Kaspera R., Totah R.A. Epoxyeicosatrienoic acids: Formation, metabolism and potential role in tissue physiology and pathophysiology. Expert Opinion on Drug Metabolism & Toxicology 2009, 5:757-771.
71. Kehl F., Cambj-Sapunar L., Maier K.G., Miyata N., Kametani S., Okamoto H., et al. 20-HETE contributes to the acute fall in cerebral blood flow after subarachnoid hemorrhage in the rat. American Journal of Physiology. Heart and Circulatory Physiology 2002, 282:H1556-H1565.
72. Kelly E.J., Nakano M., Rohatgi P., Yarov-Yarovoy V., Rettie A.E. Finding homes for orphan cytochrome P450s: CYP4V2 and CYP4F22 in disease states. Molecular Interventions 2011, 11:124-132.
73. Khanapure S.P., Garvey D.S., Janero D.R., Letts L.G. Eicosanoids in inflammation: Biosynthesis, pharmacology, and therapeutic frontiers. Current Topics in Medicinal Chemistry 2007, 7:311-340.
74. Kikuta Y., Kusunose E., Endo K., Yamamoto S., Sogawa K., Fujii-Kuriyama Y., et al. A novel form of cytochrome P-450 family 4 in human polymorphonuclear leukocytes. cDNA cloning and expression of leukotriene B4 omega-hydroxylase. The Journal of Biological Chemistry 1993, 268:9376-9380.
75. Kikuta Y., Kusunose E., Kusunose M. Characterization of human liver leukotriene B(4) omega-hydroxylase P450 (CYP4F2). Journal of Biochemistry 2000, 127:1047-1052.
76. Kikuta Y., Kusunose E., Kusunose M. Prostaglandin and leukotriene omega-hydroxylases. Prostaglandins & Other Lipid Mediators 2002, 68-69:345-362.
77. Kikuta Y., Kusunose E., Sumimoto H., Mizukami Y., Takeshige K., Sakaki T., et al. Purification and characterization of recombinant human neutrophil leukotriene B4 omega-hydroxylase (cytochrome P450 4F3). Archives of Biochemistry and Biophysics 1998, 355:201-205.
78. Kirton J.P., Xu Q. Endothelial precursors in vascular repair. Microvascular Research 2010, 79:193-199.
79. Kodani S.D., Hammock B.D. The 2014 bernard B. Brodie award lecture-epoxide hydrolases: Drug metabolism to therapeutics for chronic pain. Drug Metabolism and Disposition 2015, 43:788-802.
80. Kofeler H.C., Fauland A., Rechberger G.N., Trotzmuller M. Mass spectrometry based lipidomics: An overview of technological platforms. Metabolites 2012, 2:19-38.
81. Konkel A., Schunck W.H. Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids. Biochimica et Biophysica Acta 2011, 1814:210-222.
82. Kovarik J.M., Dole K., Riviere G.J., Pommier F., Maton S., Jin Y., et al. Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition. Journal of Clinical Pharmacology 2009, 49:212-218.
83. Kroetz D.L., Xu F. Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation. Annual Review of Pharmacology and Toxicology 2005, 45:413-438.
84. Kroot J.J., Laarakkers C.M., Geurts-Moespot A.J., Grebenchtchikov N., Pickkers P., van Ede A.E., et al. Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clinical Chemistry 2010, 56:1570-1579.
85. Kumarakulasingham M., Rooney P.H., Dundas S.R., Telfer C., Melvin W.T., Curran S., et al. Cytochrome p450 profile of colorectal cancer: Identification of markers of prognosis. Clinical Cancer Research 2005, 11:3758-3765.
86. Lasker J.M., Chen W.B., Wolf I., Bloswick B.P., Wilson P.D., Powell P.K. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. The Journal of Biological Chemistry 2000, 275:4118-4126.
87. Le Quere V., Plee-Gautier E., Potin P., Madec S., Salaun J.P. Human CYP4F3s are the main catalysts in the oxidation of fatty acid epoxides. Journal of Lipid Research 2004, 45:1446-1458.
88. Lewis D.F., Lake B.G. Molecular modelling of CYP4A subfamily members based on sequence homology with CYP102. Xenobiotica; The Fate of Foreign Compounds in Biological Systems 1999, 29:763-781.
89. Lin F., Rios A., Falck J.R., Belosludtsev Y., Schwartzman M.L. 20-Hydroxyeicosatetraenoic acid is formed in response to EGF and is a mitogen in rat proximal tubule. The American Journal of Physiology 1995, 269:F806-F816.
90. Lu A.Y., Coon M.J. Role of hemoprotein P-450 in fatty acid omega-hydroxylation in a soluble enzyme system from liver microsomes. The Journal of Biological Chemistry 1968, 243:1331-1332.
91. Madej A., Okopien B., Kowalski J., Zielinski M., Wysocki J., Szygula B., et al. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. International Journal of Clinical Pharmacology and Therapeutics 1998, 36:345-349.
92. Masters B.S., Clark J.E., Roman L.J., Nishimoto M., McCabe T.J., Ortiz de Montellano P.R., et al. Functional aspects of eicosanoid hydroxylation by lung and kidney cytochromes P450. Expression of cDNAs in mammalian cells and E. coli. Journal of Lipid Mediators 1993, 6:353-360.
93. McDonald M.G., Rieder M.J., Nakano M., Hsia C.K., Rettie A.E. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Molecular Pharmacology 2009, 75:1337-1346.
94. McMahon B., Mitchell S., Brady H.R., Godson C. Lipoxins: Revelations on resolution. Trends in Pharmacological Sciences 2001, 22:391-395.
95. Miyata N., Taniguchi K., Seki T., Ishimoto T., Sato-Watanabe M., Yasuda Y., et al. HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme. British Journal of Pharmacology 2001, 133:325-329.
96. Murphy R.C., Gijon M.A. Biosynthesis and metabolism of leukotrienes. The Biochemical Journal 2007, 405:379-395.
97. Murray G.I., Patimalla S., Stewart K.N., Miller I.D., Heys S.D. Profiling the expression of cytochrome P450 in breast cancer. Histopathology 2010, 57:202-211.
98. Murray G.I., Taylor M.C., McFadyen M.C., McKay J.A., Greenlee W.F., Burke M.D., et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Research 1997, 57:3026-3031.
99. Muthalif M.M., Benter I.F., Karzoun N., Fatima S., Harper J., Uddin M.R., et al. 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:12701-12706.
100. Nakamura T., Sato M., Kakinuma H., Miyata N., Taniguchi K., Bando K., et al. Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors. Journal of Medicinal Chemistry 2003, 46:5416-5427.
101. Nakano M., Kelly E.J., Rettie A.E. Expression and characterization of CYP4V2 as a fatty acid omega-hydroxylase. Drug Metabolism and Disposition 2009, 37:2119-2122.
102. Nakano M., Kelly E.J., Wiek C., Hanenberg H., Rettie A.E. CYP4V2 in Bietti's crystalline dystrophy: Ocular localization, metabolism of omega-3-polyunsaturated fatty acids, and functional deficit of the p.H331P variant. Molecular Pharmacology 2012, 82:679-686.
103. Naraba H., Murakami M., Matsumoto H., Shimbara S., Ueno A., Kudo I., et al. Segregated coupling of phospholipases A2, cyclooxygenases, and terminal prostanoid synthases in different phases of prostanoid biosynthesis in rat peritoneal macrophages. Journal of Immunology 1998, 160:2974-2982.
104. Nelson D.R., Zeldin D.C., Hoffman S.M., Maltais L.J., Wain H.M., Nebert D.W. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 2004, 14:1-18.
105. Nishida N., Yano H., Nishida T., Kamura T., Kojiro M. Angiogenesis in cancer. Vascular Health and Risk Management 2006, 2:213-219.
106. Node K., Huo Y., Ruan X., Yang B., Spiecker M., Ley K., et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999, 285:1276-1279.
107. Nyagode B.A., Williams I.R., Morgan E.T. Altered inflammatory responses to Citrobacter rodentium infection, but not bacterial lipopolysaccharide, in mice lacking the Cyp4a10 or Cyp4a14 genes. Inflammation 2014, 37:893-907.
108. Oliw E.H., Stark K., Bylund J. Oxidation of prostaglandin H(2) and prostaglandin H(2) analogues by human cytochromes P450: Analysis of omega-side chain hydroxy metabolites and four steroisomers of 5-hydroxyprostaglandin I(1) by mass spectrometry. Biochemical Pharmacology 2001, 62:407-415.
109. Orning L. Omega-oxidation of cysteine-containing leukotrienes by rat-liver microsomes. Isolation and characterization of omega-hydroxy and omega-carboxy metabolites of leukotriene E4 and N-acetylleukotriene E4. European Journal of Biochemistry 1987, 170:77-85.
110. Panigrahy D., Edin M.L., Lee C.R., Huang S., Bielenberg D.R., Butterfield C.E., et al. Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. The Journal of Clinical Investigation 2012, 122:178-191.
111. Panigrahy D., Kaipainen A., Greene E.R., Huang S. Cytochrome P450-derived eicosanoids: The neglected pathway in cancer. Cancer Metastasis Reviews 2010, 29:723-735.
112. Parker R.S., Sontag T.J., Swanson J.E., McCormick C.C. Discovery, characterization, and significance of the cytochrome P450 omega-hydroxylase pathway of vitamin E catabolism. Annals of the New York Academy of Sciences 2004, 1031:13-21.
113. Parkinson O.T., Kelly E.J., Bezabih E., Whittington D., Rettie A.E. Bioactivation of 4-Ipomeanol by a CYP4B enzyme in bovine lung and inhibition by HET0016. Journal of Veterinary Pharmacology and Therapeutics 2012, 35:402-405.
114. Peters-Golden M., Henderson W.R. Leukotrienes. The New England Journal of Medicine 2007, 357:1841-1854.
115. Powell W.S., Rokach J. Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid. Biochimica et Biophysica Acta 2015, 1851:340-355.
116. Powell P.K., Wolf I., Jin R., Lasker J.M. Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: Involvement of CYP4F2 and CYP4A11. The Journal of Pharmacology and Experimental Therapeutics 1998, 285:1327-1336.
117. Preiss B., Bloch K. Omega-oxidation of long chain fatty acids in rat liver. The Journal of Biological Chemistry 1964, 239:85-88.
118. Quigley R., Baum M., Reddy K.M., Griener J.C., Falck J.R. Effects of 20-HETE and 19(S)-HETE on rabbit proximal straight tubule volume transport. American Journal of Physiology. Renal Physiology 2000, 278:F949-F953.
119. Reddy J.K., Azarnoff D.L., Hignite C.E. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 1980, 283:397-398.
120. Ricciotti E., FitzGerald G.A. Prostaglandins and inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology 2011, 31:986-1000.
121. Rieger M.A., Ebner R., Bell D.R., Kiessling A., Rohayem J., Schmitz M., et al. Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. Cancer Research 2004, 64:2357-2364.
122. Rivory L.P., Slaviero K.A., Clarke S.J. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. British Journal of Cancer 2002, 87:277-280.
123. Roman R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiological Reviews 2002, 82:131-185.
124. Roman L.J., Palmer C.N., Clark J.E., Muerhoff A.S., Griffin K.J., Johnson E.F., et al. Expression of rabbit cytochromes P4504A which catalyze the omega-hydroxylation of arachidonic acid, fatty acids, and prostaglandins. Archives of Biochemistry and Biophysics 1993, 307:57-65.
125. Rose M.L., Rivera C.A., Bradford B.U., Graves L.M., Cattley R.C., Schoonhoven R., et al. Kupffer cell oxidant production is central to the mechanism of peroxisome proliferators. Carcinogenesis 1999, 20:27-33.
126. Rusyn I., Tsukamoto H., Thurman R.G. WY-14 643 rapidly activates nuclear factor kappaB in Kupffer cells before hepatocytes. Carcinogenesis 1998, 19:1217-1222.
127. Sala A., Voelkel N., Maclouf J., Murphy R.C. Leukotriene E4 elimination and metabolism in normal human subjects. The Journal of Biological Chemistry 1990, 265:21771-21778.
128. Samuelsson B., Dahlen S.E., Lindgren J.A., Rouzer C.A., Serhan C.N. Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects. Science 1987, 237:1171-1176.
129. Sari A.N., Korkmaz B., Serin M.S., Kacan M., Unsal D., Buharalioglu C.K., et al. Effects of 5,14-HEDGE, a 20-HETE mimetic, on lipopolysaccharide-induced changes in MyD88/TAK1/IKKbeta/IkappaB-alpha/NF-kappaB pathway and circulating miR-150, miR-223, and miR-297 levels in a rat model of septic shock. Inflammation Research: Official Journal of the European Histamine Research Society . . . [et al.] 2014, 63:741-756.
130. Sato M., Ishii T., Kobayashi-Matsunaga Y., Amada H., Taniguchi K., Miyata N., et al. Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor. Bioorganic & Medicinal Chemistry Letters 2001, 11:2993-2995.
131. Savas U., Hsu M.H., Griffin K.J., Bell D.R., Johnson E.F. Conditional regulation of the human CYP4X1 and CYP4Z1 genes. Archives of Biochemistry and Biophysics 2005, 436:377-385.
132. Schwartzman M.L., Falck J.R., Yadagiri P., Escalante B. Metabolism of 20-hydroxyeicosatetraenoic acid by cyclooxygenase. Formation and identification of novel endothelium-dependent vasoconstrictor metabolites. The Journal of Biological Chemistry 1989, 264:11658-11662.
133. Sehgal N., Agarwal V., Valli R.K., Joshi S.D., Antonovic L., Strobel H.W., et al. Cytochrome P4504f, a potential therapeutic target limiting neuroinflammation. Biochemical Pharmacology 2011, 82:53-64.
134. Seibert K., Zhang Y., Leahy K., Hauser S., Masferrer J., Isakson P. Distribution of COX-1 and COX-2 in normal and inflamed tissues. Advances in Experimental Medicine and Biology 1997, 400A:167-170.
135. Serhan C.N., Chiang N. Resolution phase lipid mediators of inflammation: Agonists of resolution. Current Opinion in Pharmacology 2013, 13:632-640.
136. Serhan C.N., Chiang N., Dalli J., Levy B.D. Lipid mediators in the resolution of inflammation. Cold Spring Harbor Perspectives in Biology 2015, 7:a016311.
137. Serhan C.N., Petasis N.A. Resolvins and protectins in inflammation resolution. Chemical Reviews 2011, 111:5922-5943.
138. Shak S., Goldstein I.M. Omega-oxidation is the major pathway for the catabolism of leukotriene B4 in human polymorphonuclear leukocytes. The Journal of Biological Chemistry 1984, 259:10181-10187.
139. Shibuya M. Vascular endothelial growth factor and its receptor system: Physiological functions in angiogenesis and pathological roles in various diseases. Journal of Biochemistry 2013, 153:13-19.
140. Simopoulos A.P. Omega-3 fatty acids in inflammation and autoimmune diseases. Journal of the American College of Nutrition 2002, 21:495-505.
141. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: Structural, cellular, and molecular biology. Annual Review of Biochemistry 2000, 69:145-182.
142. Smith W.L., Song I. The enzymology of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins & Other Lipid Mediators 2002, 68-69:115-128.
143. Smyth E.M., Grosser T., Wang M., Yu Y., FitzGerald G.A. Prostanoids in health and disease. Journal of Lipid Research 2009, 50(Suppl.):S423-S428.
144. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I.P., et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998, 393:790-793.
145. Stark K., Dostalek M., Guengerich F.P. Expression and purification of orphan cytochrome P450 4X1 and oxidation of anandamide. The FEBS Journal 2008, 275:3706-3717.
146. Stoilov I., Krueger W., Mankowski D., Guernsey L., Kaur A., Glynn J., et al. The cytochromes P450 (CYP) response to allergic inflammation of the lung. Archives of Biochemistry and Biophysics 2006, 456:30-38.
147. Tacconelli S., Patrignani P. Inside epoxyeicosatrienoic acids and cardiovascular disease. Frontiers in Pharmacology 2014, 5:239.
148. Theken K.N., Deng Y., Kannon M.A., Miller T.M., Poloyac S.M., Lee C.R. Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism. Drug Metabolism and Disposition 2011, 39:22-29.
149. Tradonsky A., Rubin T., Beck R., Ring B., Seitz R., Mair S. A search for reliable molecular markers of prognosis in prostate cancer: A study of 240 cases. American Journal of Clinical Pathology 2012, 137:918-930.
150. Tsikas D., Zoerner A.A. Analysis of eicosanoids by LC-MS/MS and GC-MS/MS: A historical retrospect and a discussion. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2014, 964:79-88.
151. Tunctan B., Korkmaz B., Sari A.N., Kacan M., Unsal D., Serin M.S., et al. Contribution of iNOS/sGC/PKG pathway, COX-2, CYP4A1, and gp91(phox) to the protective effect of 5,14-HEDGE, a 20-HETE mimetic, against vasodilation, hypotension, tachycardia, and inflammation in a rat model of septic shock. Nitric Oxide: Biology and Chemistry/Official Journal of the Nitric Oxide Society 2013, 33:18-41.
152. Vane J.R., Bakhle Y.S., Botting R.M. Cyclooxygenases 1 and 2. Annual Review of Pharmacology and Toxicology 1998, 38:97-120.
153. Verkade P.E., Elzas M., van der Lee J., de Wolff H.H., Verkade-Sandbergen A., van der Sande D. Untersuchungen über den Fettstoffwechsel I. Hoppe-Seyler's Zeitschrift für physiologische Chemie 1933, 215:225-257.
154. Wakabayashi K., Shimazono N. Studies on omega-oxidation of fatty acids in vitro. I. Overall reaction and intermediate. Biochimica et Biophysica Acta 1963, 70:132-142.
155. Wang D., Dubois R.N. Eicosanoids and cancer. Nature Reviews. Cancer 2010, 10:181-193.
156. Wang M.Z., Saulter J.Y., Usuki E., Cheung Y.L., Hall M., Bridges A.S., et al. CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2006, 34:1985-1994.
157. Wang M.H., Wang J., Chang H.H., Zand B.A., Jiang M., Nasjletti A., et al. Regulation of renal CYP4A expression and 20-HETE synthesis by nitric oxide in pregnant rats. American Journal of Physiology. Renal Physiology 2003, 285:F295-F302.
158. Wang Y., Zhao J., Kalsotra A., Turman C.M., Grill R.J., Dash P.K., et al. CYP4Fs expression in rat brain correlates with changes in LTB4 levels after traumatic brain injury. Journal of Neurotrauma 2008, 25:1187-1194.
159. Weigelt B., Peterse J.L., van 't Veer L.J. Breast cancer metastasis: Markers and models. Nature Reviews. Cancer 2005, 5:591-602.
160. Wiek C., Schmidt E.M., Roellecke K., Freund M., Nakano M., Kelly E.J., et al. Identification of amino acid determinants in CYP4B1 for optimal catalytic processing of 4-ipomeanol. The Biochemical Journal 2015, 465:103-114.
161. Yu M., Cambj-Sapunar L., Kehl F., Maier K.G., Takeuchi K., Miyata N., et al. Effects of a 20-HETE antagonist and agonists on cerebral vascular tone. European Journal of Pharmacology 2004, 486:297-306.
162. Yu W., Chai H., Li Y., Zhao H., Xie X., Zheng H., et al. Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer. Toxicology and Applied Pharmacology 2012, 264:73-83.
163. Yu W., Chen L., Yang Y.Q., Falck J.R., Guo A.M., Li Y., et al. Cytochrome P450 omega-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 2011, 68:619-629.
164. Zhang X., Chen L., Hardwick J.P. Promoter activity and regulation of the CYP4F2 leukotriene B(4) omega-hydroxylase gene by peroxisomal proliferators and retinoic acid in HepG2 cells. Archives of Biochemistry and Biophysics 2000, 378:364-376.
165. Zhang X., Hardwick J.P. Regulation of CYP4F2 leukotriene B4 omega-hydroxylase by retinoic acids in HepG2 cells. Biochemical and Biophysical Research Communications 2000, 279:864-871.
166. Zollner A., Dragan C.A., Pistorius D., Muller R., Bode H.B., Peters F.T., et al. Human CYP4Z1 catalyzes the in-chain hydroxylation of lauric acid and myristic acid. Biological Chemistry 2009, 390:313-317.
167. Zou A.P., Ma Y.H., Sui Z.H., Ortiz de Montellano P.R., Clark J.E., Masters B.S., et al. Effects of 17-octadecynoic acid, a suicide-substrate inhibitor of cytochrome P450 fatty acid omega-hydroxylase, on renal function in rats. The Journal of Pharmacology and Experimental Therapeutics 1994, 268:474-481.